Company (symbol)# |
Date filed |
Shares/Units (M) |
Price |
Shares out (M) |
Lead, other underwriters |
Gross (US$M) |
Adial Pharmaceuticals LLC (Charlottesville, Va.; ADIL)1 |
9/12/17 |
1.4S |
$9-$11 |
N/A |
Aegis Capital Corp. |
$16.80 |
Allena Pharmaceuticals Inc. (Newton, Mass.; ALNA) |
10/10/17 |
5.33S |
$14-$16 |
68.8 |
Credit Suisse; Jefferies; Cowen and Co.; Wedbush Pacgrow |
$79.95 |
Apellis Pharmaceuticals Inc. (Crestwood, Ky.; APLS) |
10/17/17 |
10.7S |
$13-$15 |
N/A |
Citigroup; J.P. Morgan; Evercore ISI |
$149.80 |
Arsanis Inc. (Waltham, Mass.; ASNS) |
10/24/17 |
N/A |
N/A |
N/A |
Citigroup; Cowen & Co.; Piper Jaffray |
$57.50 |
Axium Pharmaceuticals Inc. (High Point, N.C.; OTC BB)2 |
9/14/17 |
50S |
$0.10 |
95.13 |
N/A |
$5.00 |
Bioarctic AB (Stockholm; Nasdaq Stockholm) |
9/14/17 |
Class B shares |
N/A |
N/A |
DNB Markets; Carnegie Investment Bank AB |
N/A |
Destiny Pharma Ltd. (Brighton, U.K.; AIM) |
8/18/17 |
N/A |
N/A |
N/A |
N/A |
$12.90 |
Erytech Pharma SA (Lyon, France; ERYP) |
10/10/17 |
ADS |
N/A |
N/A |
Jefferies; Cowen; Oddo BHF; JMP Securities |
$100.00 |
Genprex Inc. (Austin, Texas; GNPX) |
7/24/17 |
2S-4.5S |
$5 |
N/A |
Network 1 Financial Securities Inc. |
$17.50 |
Inflarx NV (Jena, Germany; IFRX) |
10/17/17 |
6.66S |
$14-$16 |
N/A |
J.P. Morgan; Leerink Partners; BMO Capital Markets |
$99.99 |
Lysogene SA (Neuilly-sur-Seine, France; Euronext Paris:LYS)3 |
1/26/17 |
N/A |
€6.80 - €9.20 |
N/A |
N/A |
€39.7 (US$42.7) |
Rhythm Pharmaceuticals Inc. (Boston; RYTM) |
9/5/17 |
6.7S |
$14-$16 |
N/A |
Morgan Stanley; BofA Merrill Lynch; Cowen & Co.; Needham & Co. |
$115.00 |
Scpharmaceuticals Inc. (Burlington, Mass.; SCPH) |
10/25/17 |
N/A |
N/A |
N/A |
Jefferies; Leerink Partners; BMO Capital Markets |
$100.00 |
Spero Therapeutics LLC (Cambridge, Mass.; SPRO) |
10/10/17 |
5S |
$14-$16 |
51 |
BofA Merrill Lynch; Cowen and Co.; Stifel Nicolaus & Co.; Oppenheimer & Co. |
$75.00 |
|
Notes # Unless otherwise indicated, companies are filing to trade on the Nasdaq exchange. Currency conversions are based on exchange rates at the time of the deal. This chart includes only biotech companies that develop therapeutics. 1 Adial's overallotment option: 210,000 shares. 2 Axium's stockholders are selling 45.13M shares in addition. 3 Lysogene's overallotment option: 646,875 shares. | ||||||